TGFB1 and type 2 diabetes mellitus: The delayed, but sustained secretion of TGF-β1 have been reported, associated with high glucose-treated MSCs and other in vivo models of diabetic bone repair, in addition to sera derived from T2DM patients (56, 63, 73, 81–84).